The inventor, Mark Chariff, D.C., has developed a laser diode that co-propagates wavelengths simultaneously in the ranges of 532nm, 808nm, and 1064nm. These wavelengths make up one component beam. This essentially means that all three wavelengths strike the target tissue at the same time without converging or diverging. Heretofore, therapeutic lasers have used wavelengths in the ranges of 632 nm (visible) through 1064 nm (invisible) and beyond, to achieve among other uses, pain relief and tissue regeneration. Some manufacturers have built laser modules that incorporate multiple diodes propagating different wavelengths for therapeutic use. However, these devices only allow for one wavelength to irradiate a given target, since the diodes are separated. Even allowing for multiple diodes to be angulated to intersect at one point, the beams would soon diverge, defeating its purpose. Through the use of this diode on patients with a variety of acute and chronic neuro-musculoskeletal disorders, the author has observed that a large portion of these individuals experienced rapid relief from their presenting conditions. Additionally, the phenomena of sensory tingling sensation was observed in a majority of patients when the area of presumed greatest inflammation was irradiated. This phenomenon was observed in patients with visceral as well as musculoskeletal conditions. It has also been observed in patients with spinal cord injuries. Conventional wisdom in the low level therapeutic laser field would argue against the possibility of deep tissue penetration of wavelengths in the region of 532 nm and 1064 nm, two of the three components of this diode. The author’s clinical observations dispute this notion.